BioSpace2d
Vigil’s TREM2-Targeted Alzheimer’s Treatment Shows Early Promise, Moves On to Phase II
Vigil Neuroscience reported a strong safety profile and 50% sTREM2 reduction in an early-stage trial for VG-3927, potentially ...
FierceBiotech2d
Analysts 'highly encouraged' by TREM2 reduction seen in Vigil's phase 1 Alzheimer's data
Vigil Neuroscience has reported early clinical data on its Alzheimer’s disease candidate, positioning the biotech to advance its small molecule in the footsteps of AbbVie and Alector’s failed rival ...
technologynetworks2d
Lipid-Associated Macrophages Drive Liver Repair Post-Injury
Research from VIB-UGent identifies lipid-associated macrophages and LAM-like Kupffer cells as critical for liver repair. The ...
Promising Prospects for Vigil Neuroscience Inc. with VG-3927: A Groundbreaking Oral TREM2 Agonist
Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price ...
Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease
Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral ...
Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments
Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...
Research reveals how specific types of liver immune cells are required to deal with injury
Our livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...
News Medical on MSN1d
Key immune cells required for tissue repair following liver injury
Our livers contain many different types of immune cells. New research by the team of Prof. Charlotte Scott (VIB-UGent Center ...
Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3
Vigil Neuroscience Inc. (NASDAQ:VIGL) released data from its completed Phase 1 trial evaluating VG-3927 as a potential ...
The Pharma Letter1d
Vigil moves into Phase II with Alzheimer's pill
Vigil Neuroscience advances VG-3927, a small molecule TREM2 agonist, into Phase II Alzheimer’s trials in Q3 2025 following ...
Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update)
Vigil Neuroscience (VIGL) stock rises as the Sanofi (SNY)-backed biotech plans to advance its Alzheimer's candidate VG-3927 ...